Substance Use Disorder
Substance Use Disorder SUD
At Bella Vida TMS, SUD care begins with a thorough medical and psychosocial assessment and a plan tailored to your goals. For opioid use disorder, we offer medication-assisted treatment with Brixadi®—weekly then monthly buprenorphine injections—paired with counseling and recovery supports. Our nurse practitioners manage co-occurring depression, anxiety, or trauma and, when appropriate, add TMS to help regulate mood and craving circuitry. We coordinate therapy, IOP/residential partners, urine-toxicology and PDMP monitoring, relapse-prevention skills, and family involvement. In-person or telehealth; insurance-friendly, including AHCCCS.
Accepting Most Major Insurance Companies:
Don't Take our Word For It.
Third Party Studies:
SAMHSA TIP 63: Medications for Opioid Use Disorder (Full PDF) – Comprehensive national guidance on using buprenorphine, methadone, and naltrexone within whole-person care.
https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdfSAMHSA TIP 63 (Resource Page) – Overview, downloads, and companion materials for clinicians and programs.
https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002FDA: BRIXADI Prescribing Information (Label) – Official dosing, safety, REMS details, and clinical-study summaries.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210136Orig1s000lbl.pdfFDA Press Announcement: BRIXADI Approval – FDA summary of weekly and monthly buprenorphine injection indications.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorderFDA: MOUD Information Hub – Current list of FDA-approved medications for OUD and key safety guidance.
https://www.fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud
ClinicalTrials.gov NCT02651584 (Phase 3, Noninferiority Trial) – Weekly/monthly depot buprenorphine vs daily sublingual buprenorphine/naloxone.
https://clinicaltrials.gov/study/NCT02651584ClinicalTrials.gov NCT02611752 (Opioid Blockade Study) – Hydromorphone challenge demonstrating receptor blockade and withdrawal suppression with weekly depot.
https://clinicaltrials.gov/study/NCT02611752ClinicalTrials.gov NCT02710526 (PK Bridging Study) – Pharmacokinetics supporting transition from transmucosal buprenorphine to subcutaneous depot.
https://clinicaltrials.gov/study/NCT02710526?tab=resultsFDA: BRIXADI REMS Fact Sheet – Requirements and logistics for clinic administration and patient access.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210136Orig1s000REMS.pdfPubMed (JAMA Netw Open, 2024): ER Injection vs Sublingual – Post-hoc trial analysis suggests ER buprenorphine may reduce fentanyl use more effectively in some patients.
https://pubmed.ncbi.nlm.nih.gov/38916892/
Contact Us
Get Help Now
Contact our TMS clinic to receive expert, personalized care and innovative treatments that effectively address your mental health needs.
Contact Form
"*" indicates required fields